Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) had its price objective dropped by stock analysts at The Goldman Sachs Group from $12.00 to $8.00 in a research report issued on Tuesday, Benzinga reports. The brokerage currently has a “neutral” rating on the stock. The Goldman Sachs Group’s price target points to a potential downside of […]
Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) had its price target cut by investment analysts at Robert W. Baird from $18.00 to $11.00 in a note issued to investors on Tuesday, Marketbeat.com reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s price target indicates a potential upside of 6.80% from […]
Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) was downgraded by analysts at KeyCorp from an “overweight” rating to a “sector weight” rating in a research report issued on Tuesday, MarketBeat Ratings reports. Several other analysts have also weighed in on MRVI. Deutsche Bank Aktiengesellschaft lowered their target price on Maravai LifeSciences from $25.00 to $23.00 […]
Maravai LifeSciences (NASDAQ:MRVI – Get Free Report) had its price target reduced by equities research analysts at Royal Bank of Canada from $20.00 to $18.00 in a research note issued on Tuesday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Royal Bank of Canada’s price objective indicates a potential upside of […]
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) has earned an average rating of “Hold” from the nine ratings firms that are covering the firm, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12-month price […]